Celon Pharma (WAR:CLN) FFO


WAR:CLN Celon Pharma SA WAR:CLN
57 GF Score
Price zł19.86
GF Value zł22.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma FFO?

FFO (Funds from operations) only applies to REITs.

WAR:CLN
57GF Score
Celon Pharma SA WAR:CLN
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł19.86 is trading 12.2% below its estimated GF Value™ of zł22.61. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

  • FFO:
  • GF Value™: zł22.61 vs. price of zł19.86 (12.2% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
57GF Score

Get the complete analysis for WAR:CLN

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.86
Price
zł22.61
GF Value